







Leading European Nephrology

Estimated Glomerular Filtration Rate: Do We Measure The Real Renal Function Or Are We Still Groping In The Dark?

<u>Francesco Trevisani ¹</u>Umberto Capitanio¹, Alessandro Larcher¹, Luigi Gianolli², Alessandra Cinque¹, Arianna Bettiga¹, Riccardo Vago¹, Lina Bua¹,Cristina Carenzi¹, Fabio Benigni¹, Fabio Muttin¹, Andrea Salonia¹, Alberto Briganti¹, Natalia Negrin³, Ana Gonzales Rinne³, Armando Torres³, Sergio Luis Lima³, Esteban Porrini³, Francesco Montorsi¹

<u>¹Unit of Urology</u>, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
<u>²Unit of Nuclear Medicine</u>, IRCCS Ospedale San Raffaele, Milan, Italy.
<u>³University Hospital of the Canary Island</u>, Nephrology Department, La Laguna, Tenerife, Spain-University of La Laguna, Tenerife, Spain

INTRODUCTION

An accurate assessment of renal function is mandatory in the majority or urological and oncological patients to prevent renal impairment and cancer non-related deaths. Nowadays, the large part of clinicians apply CKD-EPI/MDRD formulas or 24h creatinine clearance to determine the glomerular filtration rate (GFR) before and after renal surgery (for cancer, donation, stones and pyelouretheral junction stenosis) and in metastatic patients for establish the right oncological treatment. Unfortunately, estimated GFR (eGFR) displays a wide error in reflecting real kidney function with measured GFR (mGFR) and this may lead to important consequences in the correct evaluation of patients.

RESULTS

The agreement between formulas and mGFR was poor. The TDI for MDRD was 72% and for CKD-EPI was 65%, indicating that 90% of the estimations for both formulas were included within a margin of error from mGFR of about ± 72 to 80%. CCC for MDRD was 0.75 and for CKD-EPI was 0.79, indicating poor concordance between eGFR and mGFR Moreover, the discrepancy between mGFR and GFR estimated with MDRD formula was of 19% in CKD I, 61% in CKD II, 61% in CKD IIIa, 55% in CKD IIIb, 79% in CKD IV, 100% in CKD V stage instead the discrepancy between mGFR and GFR estimated with CKD-EPI formula was of 23% in CKD I, 60% in CKD II, 40% in CKD IIIa, 57% in CKD IIIb, 80% in CKD IV, 100% in CKD V stage.

MATERIAL and METHODS

A retrospective and prospective study based on 200 pts with urooncological cancer or renal functional diseases (UOCRD) was performed in two different centers to compare eGFR formula with gold standard method renal scintigraphy or iohexol clearance. The agreement between eGFR and mGFR was evaluated using total deviation index (TDI), coverage probability (CP) and concordance correlation coefficient (CCC).

Table 1 Descriptive analysis

Age, year	58		
Median	60		
IQR	45-72		
Gender			
Male	100 (50%)		
Female	100 (50%)		
Diseases			
UROLOGICAL CANCER	18 (9%)		
NON-UROLOGICAL CANCER	21 (10.5%)		
CKD	8 (4%)		
STONES	34 (17%)		
GPU	36 (18%)		
ARTERIAL STENOSIS	2 (1%)		
TYPE 2 DM	1 (0.5%)		
HYDRONEPHROSIS/ URETHERAL KINKING	8 (4%)		
KIDNEY DONOR/TPX	28 (14%)		
SOLITARY KIDNEY	12 (6%)		
NEUROLOGICAL DISORDER	3 (1.5%)		
OTHER	29 (14.5%)		

Table 2 GFR discrepancy (ml/min) between CKD-EPI formula, MDRD formula and Gold Standard Method

GFR DISCREPANCY (ml/min/1.73m ²)	e-GFR CKD-EPI vs. MDRD		e-GFR CKD-EPI vs. gold standard method		e-GFR MDRD vs. gold standard method	
	Total	%	Total	%	Total	%
0 <gfr<10< th=""><th>160</th><th>80</th><th>75</th><th>37.5</th><th>75</th><th>37.5</th></gfr<10<>	160	80	75	37.5	75	37.5
10≤GFR<20	29	14.5	32	16	31	15.5
GFR≥ 20	11	5.5	93	46.5	94	47

Histogram 1 Serum creatinine value and creatinine-based estimates of relative GFR from different patients

0,87

150

140

eGFR CKD-EPI

T



eGFR CATEGORY (ml/min/1.73m ²)	MDRD formula	CKD-EPI formula	mGFR gold standard method	CKD-EPI formula/ MDRD formula	CKD-EPI formula/ gold standard method	MDRD formula/ gold standard method
Class1	42-21%	62-31%	86-43%	22-35.5%	14-22.6%	8-19%
Class2	87-43.5%	75-37.5%	48-24%	10-13.3%	45-60%	53-60.9%
Class3a	23-11.5%	15-7.5%	31-15.5%	0	6-40%	14-60.9%
Class3b	31-15.5%	30-15%	27-13.5%	0	17-56.7%	17-54.8%
Class4	14-7%	15-7.5%	8-4%	1-6.7%	12-80%	11-78.6%
Class5	3-1.5%	3-1.5%	0	0	3-100%	3-100%
Total T-test				0.299	0.008	0.0003

CONCLUSION

CKD-EPI and MDRD formulas may over or underestimate mGFR in pts, generating false evaluations in the clinical management and drug therapies for oncological, urological and kidney donor patients. We suggest to use a gold standard technique of mGFR (eg renal scintigraphy, iohexol measurement) in selected cases when GFR is crucial to determine the surgical/therapeutic approach. **Table 4** Agreement between eGFR and mGFR

	CCC	TDI	СР	
eGFR CKD-EPI	0.79 (0.74)	65.10 (72.20)	0.24 (0.22)	
eGFR MDRD	0.7 <i>5 (0.</i> 70)	71.65 (79.52)	0.22 <i>(0.2</i> 1)	

Contact trevisani.francesco1@gmail.com

Acknowledgments

All these notes and proceedings are confidential. You are bound not to communicate or disclose these information and results to any third party





•com